Skip to main content

NCT00202852 - A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate

A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate


CSR Summary

Not Available


Data Specification

Not Available


Annotated CRF

Not Available

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.

Product Info

Generic Name
Infliximab
Product Name
REMICADE®
Therapeutic Area
Muscle, Bone, and Cartilage Diseases
Enrollment
143
% Female
89.5%
% White
N/A
Product Class
Antirheumatic Agents - Biologic Response Modifiers
Sponsor Protocol Number
P04280
Data Holder
Johnson & Johnson
Condition Studied
Arthritis, Rheumatoid
Mean/Median Age (Years)
49.0

Supporting Documentation

Data Definition Specification Available
Annotated Case Report Form Available
Clinical Study Report
Protocol with Amendments
Study Phase 
3
Additional Information: 

Please note: individual participant-level data are not available for this trial. Only the protocol and full clinical study report are available.

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.